Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
3.380
-0.090 (-2.59%)
Apr 29, 2026, 10:48 AM EDT - Market open
Exicure Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
21.54M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Barinthus Biotherapeutics | 14.97M |
| Curis | 9.44M |
| Marker Therapeutics | 3.55M |
| OSR Holdings | 2.91M |
| Vistagen Therapeutics | 789.00K |
| VYNE Therapeutics | 570.00K |
| Lexaria Bioscience | 368.00K |
| Allarity Therapeutics | 320.00K |
XCUR News
- 6 days ago - Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) - GlobeNewsWire
- 26 days ago - Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions - GlobeNewsWire
- 4 weeks ago - Exicure, Inc. Reports Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - GlobeNewsWire
- 3 months ago - Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings - GlobeNewsWire
- 5 months ago - Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial - Benzinga
- 5 months ago - Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting - GlobeNewsWire
- 6 months ago - Exicure, Inc. Reports Third Quarter 2025 Financial Results - GlobeNewsWire